Branded PPI denied for failing step therapy by Aetna?

Aetna's specific coverage criteria for branded ppi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Applies Step Therapy to Branded PPIs

Aetna's step-therapy protocol for branded proton pump inhibitors requires members to first try and document the failure of one or more formulary-preferred generic PPIs before the branded product will be approved. This is among the most common denial types for this drug class and also among the most successfully overturned — provided the appeal clearly documents each required step with dates, clinical response, and outcomes rather than a general statement that generics "didn't work."

## Federal Appeal Rights

Step-therapy denials are pre-service coverage determinations appealable under ACA §2719 (non-ERISA plans) and ERISA §503 (self-funded plans). Most states have enacted step-therapy override laws that require insurers to grant exceptions when a required step drug is contraindicated, was previously tried and failed, or when requiring the step would cause clinically significant harm — check whether your state's law applies to your plan type. After the internal appeal, independent external review is available through an IRO; file within four months of the final internal denial. Expedited review (72 hours) applies when delay creates urgent health risk.

## Appeal Process and Timeline

1. Review Aetna's step-therapy criteria from the denial letter or its published Pharmacy Clinical Policy — identify exactly which steps are required and what constitutes documented failure. 2. Compile prior-step evidence or invoke a step-therapy exception if a required step was already tried, is contraindicated, or poses unacceptable risk. 3. File the internal appeal within the plan deadline, attaching all supporting documentation. 4. Escalate to external review if the internal appeal fails.

## Documentation to Gather

• Step-drug trial records: for each required generic PPI, provide pharmacy dispensing records showing the fill date and quantity, office notes documenting the trial, a recorded clinical outcome, and — if applicable — a note documenting adverse effects or treatment failure with specific dates.
• Contraindication or intolerance documentation: if a required step drug cannot safely be used, provide chart notes, allergy records, or a prescriber statement explaining why.
• Diagnosis and severity records: endoscopy reports, pH studies, pathology, or specialist evaluations establishing the condition and its severity.
• Prescriber step-therapy exception letter: a clinician narrative explaining why each required step has been completed or why an exception is warranted, aligned to the state or plan step-therapy exception criteria.

## Criteria-Mapping Strategy

Obtain Aetna's current Pharmacy Clinical Policy for step therapy in the PPI class and the FDA-approved prescribing label for the requested branded PPI. Build a step-by-step grid: required step in column 1, date and outcome documented in the chart in column 2, supporting exhibit in column 3. Submit this grid as the appeal cover sheet. External IRO reviewers consistently look for this type of organized evidence over narrative-only submissions.